Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study
Status:
Recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
The study aim to Evaluate the combination of ididilimumab and docetaxel alone in the
treatment of previous platinum-containing double-drug chemotherapy according to RECIST
1.1Objective remission rate of advanced or metastatic non-small cell lung cancer with
negative, driving gene negative (EGFR, ALK, ROS1); (ORR).